CMS’s Own Data Do NOT Support Claims on Part B Drug Spending

Posted

BIOtech Now Dan Durham In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for Politico Pulse note: “The agency [Centers for Medicare & Medicaid Services] on Friday announced a $9 monthly premium increase and $13 annual deductible hike, but argued that the White House is working to bring down cost […]

In Speaker Pelosi’s Extreme Drug Pricing Bill, Funding for NIH is MIA

Posted

BIOtech Now Brian Newell Supporters of Speaker Pelosi’s extreme drug pricing bill (H.R. 3) want us to believe that they can destroy the biopharmaceutical industry and still produce new cures and treatments for patients in need. The crux of this fairy tale is the promise by supporters of H.R. 3 to reinvest “savings” from the […]

#BIOSummit19 Concludes with Message of Hope Offered by Innovation

Posted

BIOtech Now Theresa Brady Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event’s chief convener, added: “I am […]

#BIOSummit19: Education and Partnerships Raise Awareness

Posted

BIOtech Now Theresa Brady When Mark Dant’s son Ryan was first diagnosed with MPS-I, a rare genetic disorder that leads to organ damage, he had to buy a medical dictionary in order to decipher the words the doctors were saying to him. “I didn’t understand the language of the scientists,” Dant recalled. “The key for […]

Investment Crackdown Prompts Chinese Investors to Leave U.S. Biotech Market and Focus on Europe

Posted

BIOtech Now Rufael Seyum Confusion among Chinese investors about shifting U.S. regulatory policy is draining billions of dollars from the American biotechnology sector and stressing startups that rely on foreign capital to cure disease. That was the message of James Huang, a managing partner in Kleiner Perkins’s China office who specializes in facilitating cross-border deal financing. […]

BIO Mourns Passing of Dr. John Holaday

Posted

BIOtech Now Jim Greenwood On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away. Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed […]

#TBT: Debunking Some Common Myths on Patent Protections

Posted

BIOtech Now Andrew Segerman The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is set to examine the U.S. patent system this morning. Ahead of the hearing – and in honor of #ThrowBackThursay – we are resurfacing a piece by BIO’s Tom DiLenge that helps debunk some of the most common […]

The Challenges and Risks of Adopting Foreign Price Controls

Posted

BIOtech Now Andrew Segerman The Trump Administration is moving forward with a plan to import foreign price controls into Medicare. Under the proposed International Pricing Index (IPI) model, the federal government would move away from a long-standing market-based reimbursement system to one that is tied to prices paid in countries with single-payer health care systems. […]

As Mosquito Fears Rise, EPA Considers Oxitec 2nd Generation Trial

Posted

BIOtech Now Karen Batra Most people consider mosquitoes to be a summertime pest – the unwelcome guest at the backyard barbecue. More concerning are the threats from disease-carrying mosquitoes, those that can potentially result in Dengue, West Nile, Yellow fever and Zika. And now media are reporting alarming cases of Eastern equine encephalitis (EEE) in […]

ICYMI: Biopharmaceutical Companies Aren’t Free-Riding on Government Research

Posted

BIOtech Now Andrew Segerman Writing for the Boston Globe, Dr. Michael Rosenblatt, chief medical officer of the venture firm Flagship Pioneering, debunks the common myth that biopharmaceutical companies are “free-riding” on government research. Policymakers in Washington have long preferred to believe that scientists and researchers funded by federal taxpayer dollars discover medicines on their own, […]

Discrimination Against Vulnerable Patients Is Nothing New

Posted

BIOtech Now Andrew Segerman Transformative therapies are advancing like never before, and a new class of medicines are changing the way we treat the world’s most devastating and debilitating diseases. Yet while innovative biopharmaceutical companies are doing their part in developing lifesaving products for patients, discriminatory insurance barriers are often standing in the way. Insurance […]

National Immunization Awareness Month Is a Reminder About the Value of Vaccines

Posted

BIOtech Now Andrew Segerman Writing for Morning Consult, Dr. Judy Monroe, president and CEO of the CDC Foundation, highlights the importance of immunization as August marks National Immunization Awareness Month. “As an international public health community, we have eradicated the scourge of smallpox thanks to Edward Jenner’s research and the development of the world’s first […]

The BIO Investor Forum Links Promising Early-Stage Technologies with an Active Investor Network

Posted

BIOtech Now Nareg Sagherian As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in 2018.  In 2018, venture capital funding of private […]

New Coalition to Raise Awareness of Antimicrobial Resistance Threat, Call for Urgent Solutions

Posted

BIOtech Now Andrew Segerman The Biotechnology Innovation Organization (BIO), leading scientists, public policy experts, and industry leaders today announced the launch of “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance and advocate for policies that accelerate the creation of new medicines. Each year, it […]

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

Posted

BIOtech Now Andrew Segerman BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford. Watch the full segment below. Full […]

Biotech Leaders Warn: Shortsighted Policies Threaten Miracle Breakthroughs

Posted

BIOtech Now Andrew Segerman Writing for STAT News, Paul Hastings – CEO of Nkarta Therapeutics and Vice Chair of BIO’s Board – warns that bad actors in the sector, as well as shortsighted proposals in Washington DC, threaten to derail a coming wave of biomedical innovation. Biomedical innovation is currently being jeopardized by a well-publicized […]

Why Are Patients Facing Higher Costs When They Go to the Pharmacy?

Posted

BIOtech Now Andrew Segerman BIO is out with a new whiteboard video that explores why more and more patients are facing higher costs when they go to the pharmacy to buy their prescription drugs. See how rebates and discounts within the drug cost ecosystem are often not used by insurers to lower patients’ out-of-pocket drug […]

Technology to Fight Malaria, Zika, and Other Mosquito-Related Diseases Is Being Blocked. Why?

Posted

BIOtech Now Josh Falzone Every year, mosquitos infect 500 million people with diseases and mosquito-borne illnesses claim nearly a million lives. Mosquito-related diseases—like malaria, West Nile, and Zika—have proven difficult to control in certain parts of the world, like Africa. But controlling diseases is not a long-term or sustainable solution. Instead, how can we eliminate […]